R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: A multicentre, prospective study

Hematological Oncology

Volumn 26, Issue 1, 2008, Pages 27-32

  Rueda, Antonio ^a   Sabin, Pilar ^b   Rifá, Juli ^c   Llanos, Marta ^d   Gómez Codina, José ^e   Lobo, Francisco ^f   García, Ramón ^g   Herrero, Joaquin ^h   Provencio, Mariano ⁱ   Jara, Carlos ^j  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^g Medical Oncology Service   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

more..

Author keywords

CHOP; Lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; ANAPHYLAXIS; ANEMIA; ARTICLE; B CELL LYMPHOMA; BLOOD CELL COUNT; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INFECTION; LARGE CELL LYMPHOMA; LIVER TOXICITY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SEPTIC SHOCK; STOMACH PERFORATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PILOT PROJECTS; PREDNISONE; PROSPECTIVE STUDIES; VINCRISTINE;

EID: 41349111128     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.829     Document Type: Article

References (21)

1. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxydaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-1493.
2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
3. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
4. Feugier P, van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large-B-cell lymphoma: a study by the Groupe d́Etude des Lymphomes de ĺAdulte. J Clin Oncol 2005; 23: 4117-4126.
5. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
6. Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-633.
7. Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
8. Pfreundschuh M, Kloess M, Zeynalova S, et al. Six vs. Eight cycles of bi-weekly CHOP-14 with or without Rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the completed RICOVER-60 trial of the German high-grade non-hodgkin lymphoma study group (DSHNHL). Blood 2006; 108(Suppl 11): abstract 205.
9. World Health Organization Classification of Tumours. In Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Jaffe ES, Harris NL, Stein H (eds). International Agency For Research On Cancer: Lyon, France, 2001.
10. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-hodgkin's lymphoma prognostic factors project. N Engl J Med 1993; 329: 987-994.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
12. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
15. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39.
16. Rigacci L, Nassi L, Alterini R, et al. Dose-dense CHOP plus rituximab (R-CHOP-14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study. Acta Haematol 2006; 115: 22-27.
17. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large-B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006; 91: 496-502.
18. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472-2479.
19. Halaas JH, Moskowitz CH, Horwitz S, et al. RCHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymph 2005; 46: 541-547.
20. Pfreundschuh M, Kloess M, Schmits R, et al. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with DLBCL: results of the RICOVER-60 trial of the German high-grade non-hodgkin lymphoma study group (DSHNHL). Blood 2005; 106(Suppl 11): abstract 13.
21. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.